http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006145961-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-34 |
| filingDate | 2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006145961-A |
| titleOfInvention | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES |
| abstract | 1. A cholesterol reverse transport mediator having a structure of A, B, and C can be arranged in any order and where A contains an acidic moiety including an acidic group or its bioisostere; B contains an aromatic or lipophilic moiety including at least a portion of the HMG-inhibitor CoA reductase or its analogue; IS contains the main fragment, including the main group or its bioisostere. 2. The mediator according to claim 1, wherein at least one of the alpha amino or alpha carboxy groups is removed from the corresponding amino or carboxy terminal terminal. The mediator according to claim 1 or 2, where, if not removed, then the alpha-amino group is protected by a protective group selected from formyl, acetyl, phenylacetyl, benzoyl, pivolyl, 9-fluorenylmethyloxycarbonyl, 2-naphthalene acid, nicotinic acid, CH- (CH ) -CO-, where n takes integer values from 1 to 20, di-tert-butyl-4-hydroxyphenyl, naphthyl, substituted naphthyl, FMOC, biphenyl, substituted phenyl, substituted heterocyclyl, alkyl, aryl, substituted aryl, cycloalkyl , fused cycloalkyl, saturated heteroaryl, substituted saturated heteroaryl. 4 . The mediator according to claim 1 or 2, where, if not removed, then the alpha-carboxy group is protected by a protective group selected from the group consisting of an amine, such as RNH, where R = H, di-tert-butyl-4-hydroxy- phenyl, naphthyl, substituted naphthyl, FMOC, biphenyl, substituted phenyl, substituted heterocyclyl, alkyl, aryl, substituted aryl, cycloalkyl, condensed cycloalkyl, saturated heteroaryl and substituted saturated heteroaryl. 5. The mediator according to claim 1, where the bioisostere of the acid group is selected from the group consisting of: 6. The mediator according to claim 1, where the bioisoster of the main group |
| priorityDate | 2004-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.